Phase II Single-arm Clinical Study of the Efficacy and Safety of Pucotenlimab in Combination With Vorolanib Neoadjuvant Therapy for Patients With High-risk Renal Carcinoma Indicating Partial Nephrectomy
Latest Information Update: 09 Feb 2026
At a glance
- Drugs Pucotenlimab (Primary) ; Vorolanib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
Most Recent Events
- 09 Feb 2026 New trial record